Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL: Targeted Immunotherapy in Pediatric Lymphoma
NCT05253495Phase 2Recruiting
- Sponsor
- New York Medical College
- Start
- Feb 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin, nivolumab in mature B-cell non-Hodgkin lymphoma, classical Hodgkin lymphoma (cHL), sponsored by New York Medical College. Started Feb 2022; status: recruiting.
02
Drugs
polatuzumab vedotinnivolumab
03
Conditions
mature B-cell non-Hodgkin lymphomaclassical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05253495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253495.